Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25080919 | 1.00 | CHRM2 (0.31) | CHRM2CHRM4CHRM1CHRM3HPGD | |
| SCHEMBL25897662 | 0.86 | CES2 (0.36) | CHRM2CHRM4CHRM1CHRM3HPGD | |
| SCHEMBL21100032 | 0.86 | CES2 (0.36) | CHRM2CHRM4CHRM1CHRM3HPGD | |
| SCHEMBL21099778 | 0.86 | CES2 (0.36) | CHRM2CHRM4CHRM1CHRM3HPGD | |
| SCHEMBL22548934 | 0.84 | — | — | |
| SCHEMBL26382546 | 0.82 | NPSR1 (0.32) | — | |
| SCHEMBL21100174 | 0.82 | NPSR1 (0.32) | — | |
| SCHEMBL22648256 | 0.82 | NPSR1 (0.32) | — | |
| SCHEMBL21100451 | 0.82 | CHRNB2 (0.32) | — | |
| SCHEMBL12826153 | 0.79 | ACE (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689430-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190177393-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177393-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | CHRM2 954/4885CHRM4 930/4885CHRM1 830/4885 |
| US-10689430-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | CHRM2 954/4885CHRM4 930/4885CHRM1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.